Incyte (INCY) Is Up 6.2% After Positive Povorcitinib Data And New Oncology Collaboration - Has The Bull Case Changed? [Yahoo! Finance]
Incyte Corporation (INCY)
Last incyte corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
incyte.com/ir/investor-overview.aspx
Company Research
Source: Yahoo! Finance
and Adagene announced entering a clinical collaboration with Incyte to test a combination immunotherapy regimen in advanced microsatellite stable colorectal cancer. Together with recent leadership changes, these developments highlight Incyte's push to build a broader immunology and oncology franchise around both late-stage and early pipeline assets. We'll now examine how the strong 54-week povorcitinib data may reshape Incyte's investment narrative and risk-reward profile. Find 58 companies with promising cash flow potential yet trading below their fair value Incyte Investment Narrative Recap To own Incyte, you need to believe its expanding immunology and oncology portfolio can gradually reduce dependence on Jakafi while supporting disciplined R&D and commercial spending. The strongest near term catalyst is the HS regulatory outcome for povorcitinib in the US and EU, and the new 54 week data directly reinforce that story. At the same time, execution risk around the broader l
Show less
Read more
Impact Snapshot
Event Time:
INCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INCY alerts
High impacting Incyte Corporation news events
Weekly update
A roundup of the hottest topics
INCY
News
- Incyte (INCY) was upgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "hold (c+)" to "buy (b-)".MarketBeat
- Stocks hedge funds love [Seeking Alpha]Seeking Alpha
- A Look Back at Biotechnology Stocks' Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack [Yahoo! Finance]Yahoo! Finance
- Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual MeetingBusiness Wire
INCY
Earnings
- 2/10/26 - Beat
INCY
Sec Filings
- 4/2/26 - Form 4
- 4/2/26 - Form 4
- 4/2/26 - Form 4
- INCY's page on the SEC website